Market Report Source

Overview

The purpose of this report is to analyze and describe the nuclear cardiology market segments in the U.S. and worldwide. It examines the measurement devices that are utilized by physicians to diagnose and monitor heart diseases. This study also discusses key products in nuclear cardiology and examines the trends that are stimulating this market. It includes a survey of all major companies actively engaged in marketing, manufacturing or developing nuclear cardiological instrumentation, with each company discussed in depth. The main objectives of this analysis are to:

• Identify viable technology drivers through a comprehensive look at platform technologies for nuclear cardiology testing.

• Obtain a complete understanding of the individual nuclear cardiology testing platforms from their basic principles to their clinical applications.

• Discover feasible market opportunities by identifying high-growth applications in different clinical diagnostic areas.

• Focus on global industry developments through an in-depth analysis of the major world markets for nuclear cardiology technology, including growth forecasts.

• Present market figures related to the current value of nuclear cardiology, market projections, market share, key players, and sector growth rates.

An analysis of the nuclear cardiology market must include several key areas of related activity. The most important segments discussed in this report include:

• Hardware (e.g., nuclear cardiology instrumentation).
• Software (e.g., nuclear cardiology image processing, PACS).
• Radiopharmaceuticals and pharmaceuticals.
• Ancillary products.
• Service and support.

Table of Contents

1. Overview 5
1.1 Objectives 5
1.2 Scope 6
1.3 Methodology 6
1.4 Executive Summary 6

2. Medical Imaging Market Analysis 10
2.1 Medical Imaging Industry Market Size 10
2.2 Medical Imaging Infrastructure 11
2.2.1 Total Healthcare Expenditures and Demographics 11
2.2.2 Number of Hospitals 12
2.2.3 Number of Radiologists 13
2.2.4 Radiology Services 14
2.2.5 Medical Imaging Companies 16
2.2.6 Market Drivers 16
2.2.6.1 Product Enhancements 17
2.2.6.2 Contrast Agents Development 17
2.2.6.3 Innovation 17
2.2.7 Market Restraints 18
2.2.8 Market Segments for Medical Imaging 18
2.2.8.1 Discovery 18
2.2.8.2 Clinical Applications 19
2.2.8.3 Clinical Trials 19
2.2.8.4 Outpatient Facilities 19
2.2.8.5 Technology Advances in Diagnostic Imaging Modalities 19
2.2.8.6 Safety and Ergonomics Concerns 19
2.2.8.7 Volumetric Imaging 20
2.2.8.8 Digital Radiography (DR) 20
2.2.8.9 Contrast Media 21

3. Nuclear Medicine and Nuclear Cardiology Market 29
3.1 Medical Imaging Industry Forecasts 29
3.2 Hardware Companies (Nuclear Medicine Instrumentation) 30
3.3 Software Companies (Image Processing and PACS) 30
3.4 Radiopharmaceuticals and Pharmaceuticals Companies 31
3.5 Ancillary Products Companies 31
3.6 Service and Support Companies 31
3.7 Nuclear Cardiology Market 31
3.8 Hardware (PET, SPECT and Hybrids) 33
3.8.1 Scanner Investment: Not Just a Cardiology Market 33
3.8.1.1 Impact of Alzheimer’s Reimbursement 34
3.8.2 Sales Trends for PET Scanners 34
3.8.3 Market Consolidation in the U.S. 34
3.8.4 Learning Curve Impact for PET 35
3.8.5 Hardware Market Trends 35
3.9 Software (PACS and RIS) 36
3.10 Radiopharmaceuticals 37
3.10.1 Diagnostic Radiopharmaceuticals 37
3.10.2 Therapeutic Radiopharmaceuticals 37

4. Products Analysis 38
4.1 Nuclear Medicine Instrumentation 38
4.1.1 PET Scan 38
4.1.2 SPECT Scan 39
4.1.2.1 Heart Imaging 41
4.1.3 PET Versus SPECT 42
4.1.4 Hybrid Technology 42
4.2 Image Processing: PACS 46
4.2.1 PACS and Nuclear Medicine 46
4.2.2 Difficulties in Making PACS Work with Nuclear Medicine 46
4.2.1.2 3-D and Quantitative Analysis 47
4.2.1.5 Small Market Opportunities 47
4.3 Radiopharmaceuticals and Pharmaceuticals 47
4.3.1 Introduction 47
4.3.2 Background 48
4.3.3 Areas of Current Interest 49

5. Regulations, Reimbursements and Other Issues 50
5.1 Food and Drug Administration (FDA) 50
5.1.1 FDA Guidance 50
5.1.2 FDA Nuclear Medicine Coalition 50
5.2 U.S. Nuclear Regulatory Commission (NRC) 50
5.2.1 What NRC Regulates 50
5.2.2 How NRC Regulates 51
5.2.3 Related Information 51
5.3 Memorandum of Understanding between NRC and FDA 51
5.3.1 Authorities and Regulatory Programs 51
5.4 Current NRC Issues and Actions 54
5.4.1 Meetings 54
5.4.2 Program and Policy Issues 54
5.4.3 Recently Issued Significant Enforcement Actions 55
5.4.3.1 Stark II Regulations 55
5.4.3.2 Recent Impact of Stark II Regulations 56
5.4.3.3 Reimbursement 56

6. Business Affairs (Mergers, Acquisitions and Partnerships) 57
6.1 Recent Corporate Partnerships and Mergers 57
6.2 Recent Industry Activity 57
6.3 Product Launches and Developments 58

7. Technology Trends 60
7.1 Hardware (Nuclear Medicine Instrumentation) 60
7.2 Software (PACS) 63
7.2.1 Problems Interfacing PACS and NM 64
7.2.2 SNM and IHE 64
7.2.3 IHE Nuclear Medicine Profile 64
7.2.4 What Next? 65
7.2.5 Optimal Patient Care 66
7.2.6 Four Steps to Standards Adoption 66
7.2.7 Technical Framework: Business with Technology 67
7.2.8 Leading by Example 68
7.2.9 IHE and Electronic Health Record (EHR) 68
7.3 Radiopharmaceuticals and Pharmaceuticals 68
7.3.1 Market Share 69
7.3.2 Contrast Media Market Drivers 70
7.3.3 Contrast Media Market Sector Overview 70
7.3.4 Contrast Media Market Analysis 71
7.3.5 Growth Prospects for Contrast Media 71
7.4 Market Sector Analysis 71
7.5 Leading Companies in General Medical Imaging 73

8. Company Profiles 74
8.1 Hardware (Nuclear Medicine Instrumentation) 74
8.1.1 AccuSync Medical Research 74
8.1.2 Bristol-Myers Squibb (Medical Imaging) 74
8.1.3 Capintec 75
8.1.4 CardiArc 75
8.1.5 Cardinal Health (Cardiology Solutions) 75
8.1.6 Digirad 76
8.1.7 GE Healthcare 76
8.1.8 GVI Medical Devices 77
8.1.9 Hitachi Medical Systems America 78
8.1.10 IS2 Medical Systems 79
8.1.11 Mediso 79
8.1.12 Philips Medical 80
8.1.13 Positron 81
8.1.14 Siemens Medical 81
8.1.15 Spectrum Dynamics 82
8.2 Software (Image Processing and PACS) 83
8.2.1 Heartlab 83
8.2.2 Hermes Medical Solutions 84
8.2.3 INVIA 84
8.2.4 McKesson 85
8.2.5 MedImage 85
8.2.6 MIMvista 85
8.2.7 Numa 86
8.2.8 ProSolv Cardiovascular 86
8.2.9 Scientific Imaging 86
8.2.10 Segami Corporation 86
8.2.11 Syntermed 86
8.2.12 Thinking Systems Corporation 87
8.2.13 UltraSPECT 87
8.2.14 Witt Biomedical Corporation 87
8.3 Radiopharmaceuticals and Pharmaceuticals 87
8.3.1 Astellas Pharma U.S. 87
8.3.2 Bracco Diagnostics 88
8.3.3 Isotope Products Laboratories 88
8.3.4 Izotop: Institute of Isotopes 89
8.3.5 Mallinckrodt 89
8.3.6 Merck 89
8.3.7 NuView Radiopharmaceuticals 91
8.3.8 Pfizer 91
8.3.9 Tyco Healthcare 91
8.4 Ancillary Products 92
8.4.1 CNMTStore.com 92
8.4.2 Data Spectrum Corporation 92
8.4.3 Daxor Corporation 93
8.4.4 Ivy Biomedical Systems 93
8.4.5 MarCal Medical 93
8.5 Service and Support 93
8.5.1 BC Technical 93
8.5.2 Diagnostix Plus 94
8.5.3 MedAxiom 94
8.5.4 MediNuclear Corporation (MNC) 94
8.5.5 MEDX 94
8.5.6 Pinestar Technology 95
8.5.7 Technology Imaging Services 95
8.6 Other Business Opportunities 95

9. Other Elements of Nuclear Medicine Industry 96
9.1 Nuclear Medicine: Guidelines, Certification and Societies 96
9.1.1 American College of Radiology (ACR) 96
9.1.2 American Society of Nuclear Cardiology (ASNC) 96
9.1.3 Associates in Medical Physics (AMP) 96
9.1.4 Certification Board of Nuclear Cardiology (CBNC) 96
9.1.5 ICANL 97
9.1.6 IHE 97
9.1.7 ISO 97
9.1.8 MedPage Today 97
9.1.9 Nuclear Medicine Technology Certification Board (NMTCB) 97
9.1.10 Society of Cardiovascular Computed Tomography (SCCT) 98
9.1.11 Society of Nuclear Medicine (SNM) 98
9.2 Nuclear Medicine: Publications 98
9.2.1 Elsevier 98
9.2.2 HRA Research 99
9.2.3 Lippincott Williams & Wilkins 99

INDEX OF FIGURES
Figure 3.1: U.S. Nuclear Imaging Procedures 32
Figure 3.2: Digirad—Growth of Nuclear Imaging Procedures, 2004-2006 32
Figure 4.1: Nuclear Imaging 38
Figure 4.2: PET Scan 39
Figure 4.3: SPECT Scan 40
Figure 4.4: PET-CT Scan 43
Figure 4.5: SPECT-CT Scan 45
Figure 7.1: IHE Technical Framework 66
Figure 7.2: IHE Framework Organization 67
Figure 7.3: IHE Actors and Transactions 68

INDEX OF TABLES
Table 2.1: U.S. Medical Imaging Market Size, 2001-2010 10
Table 2.2: Global Medical Imaging Market Size, 2001-2010 10
Table 2.3: U.S. Health Expenditures as a Percentage of GDP, 2000-2010 11
Table 2.4: U.S. User Expenditures for Medical Imaging Equipment and Related Products 11
Table 2.5: Millions of Americans Over 65 Years of Age, 2000-2050 12
Table 2.6: Hospital Survey 12
Table 2.7: Percent Change in Volume of Examinations per Imaging Modality, 1993-2004 15
Table 2.8: Worldwide Market Share of Medical Imaging Companies 16
Table 2.9: Worldwide Imaging Procedures, 2001 to 2010 22
Table 2.10: Data Sources for Nuclear Medicine Professionals and Facilities 27
Table 7.1: Market Share of Contrast Media Players 69
Table 7.2: Contrast Media Market Growth, 2003-2010 70
Table 7.3: Worldwide Imaging Procedures, 2001-2010 72
Table 8.1: Astellas Alliances 88